New Delhi : Global healthcare major Johnson &amp; Johnson ( J&amp;J ) on Monday said it expects to start human testing of its COVID-19 vaccine by September 2020 and anticipates that the first batch of vaccine could be available for emergency use authorisation in early 2021 .
Through a partnership , the Biomedical Advanced Research and Development Authority ( BARDA ) and Johnson &amp; Johnson together have committed more than USD 1 billion of investment to co-fund vaccine research , development , and clinical testing , Johnson &amp; Johnson said in a statement .
J&amp;J 's lead vaccine candidate will enter a phase one human clinical study by September , the company said , and clinical data on its effects is expected before the end of the year .
If the vaccine works well , the company said it could be available for emergency use in early 2021 .
As part of its commitment , Johnson &amp; Johnson is also expanding the company 's global manufacturing capacity , including through the establishment of new US vaccine manufacturing capabilities and scaling up capacity in other countries , it added .
The additional capacity will assist @ @ @ @ @ @ @ @ @ @ the supply of more than one billion doses of a safe and effective vaccine globally , the company said .
" The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible , " Johnson &amp; Johnson Chairman and CEO Alex Gorsky said .
